Clinical Trial

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Name: Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation — clinical trial record (NCT07094464)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.

Trial Details

NCT Number	NCT07094464
Lead Sponsor	Daihong Liu
Conditions	TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment	20 participants
Start Date	2025-06-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-30